Rapid response
Long COVID: The long-term health effects of COVID-19
What is Long COVID ? How many people are affected? What are the key challenges for diagnosis and treatment? What are the priority areas for research?
-
-
Rapid response
COVID-19: The Omicron Variant
The Omicron variant of the SARS-CoV-2 virus, which causes COVID-19, has been found across the world since it was first detected in early November 2021. This article describes the characteristics of the variant, why scientists are concerned, and the possible impact that it might have on the course of the pandemic.
-
Rapid response
Impact of COVID-19 on Early Childhood Education & Care
This rapid response presents current research on the impact of the pandemic on the ECEC sector in England and the impact of changes in access to ECEC on pre-school children.
-
Rapid response
Water fluoridation and dental health
An overview of water fluoridation in England, including the impact of fluoride on dental health, an overview of dental health in England, and the importance and implications of dental health inequalities.
-
Rapid response
Immunising children against COVID-19
As the UK COVID-19 immunisation programme reaches all adults, the Government has announced an update to its policy on using a COVID-19 vaccine in children. So, how does COVID-19 affect children? What will the impact of vaccinating children be on preventing disease and minimising associated risks? And what do we know about public attitudes to using COVID-19 vaccines in children?
-
Rapid response
How does the virus that causes COVID-19 spread?
What are the different mechanisms by which the novel SARS-CoV-2 coronavirus is transmitted from one person to another, how has the scientific thinking changed, and how can transmission be reduced?
-
Rapid response
COVID-19 vaccine coverage and targeted interventions to improve vaccination uptake
The COVID-19 vaccination programme launched in January 2021. All adults over 18 have now been offered the vaccine, although it was reported that 1.3 million people who had been offered a vaccine had not received it. Some people are vaccine hesitant whilst others experience barriers to accessing vaccines. Targeted interventions have been promoted locally and nationally to improve vaccine uptake.
-
Rapid response
COVID-19 vaccines: effectiveness against the B.1.617.2 variant and latest updates from trials
The B.1.617.2 variant was first observed in India and is rapidly spreading in the UK. What is known about effectiveness of vaccines against this variant - and how close to the finish line are the other vaccines already secured by the UK?
-
Rapid response
What is the real-world impact of COVID-19 vaccines on community transmission?
Real-world data shows that COVID-19 vaccines deployed in the UK are effective in protecting against SARS-CoV-2 transmission already after a single dose. Are all the other COVID-19 vaccines equally effective? What is the evidence on balancing between vaccinations and lifting restrictions?
-
Rapid response
COVID-19 vaccines safety and blood clots
The safety of COVID-19 vaccines currently deployed in the UK is closely monitored. This monitoring has shown that the University of Oxford/AstraZeneca vaccine is associated with very rare blood clots. What is known about these very rare adverse events?
-
Rapid response
COVID-19 vaccine misinformation
There have been large volumes of inaccurate information about COVID-19 circulating since the beginning of the pandemic, including misinformation about vaccinations against the infection. This article looks at the types and sources of COVID-19 vaccine misinformation and its public health impact. It also looks at the different approaches being used to fight COVID-19 vaccine misinformation, such as social media content moderation and guidance for the public.
-
Rapid response
Which SARS-CoV-2 variants reduce the effectiveness of vaccines?
New SARS-CoV-2 variants identified around the world could have an impact on current vaccination programmes. What is the latest evidence on the effectiveness of the COVID-19 vaccines used in the UK on new variants? How quickly can these vaccines be updated and approved? What alternative strategies can be used?
-
Rapid response
COVID-19 vaccines and virus transmission
COVID-19 vaccines have been deployed in the UK since December 2020. This article examines the impact of COVID-19 vaccines on transmission of the virus. It also considers the potential implications of vaccine-induced protection for easing lockdown restrictions and debate about potential introduction of immunity certification or a vaccine passport scheme.
-
Rapid response
Latest evidence on impacts of COVID-19 in children: March 2021
How does COVID-19 affect children? Will children be vaccinated against the disease? This article summarises the latest findings from research and highlights where more research can explore some of the remaining uncertainties.
-
Rapid response
Changing the UK COVID-19 vaccine dosing schedule
On December 31, 2020 the four UK Chief Medical Officers (CMOs) published a statement announcing changes to the dosing schedule for the second dose of the Pfizer/BioNTech and University of Oxford/AstraZeneca vaccines. It stated that the interval between the first and second dose should be extended from 3–4 weeks to up to 12 weeks. This rapid response examines the evidence behind this decision.
Total results (page 4 of 8)